Skip to main content
. 2016 Feb 1;10(2):e0004422. doi: 10.1371/journal.pntd.0004422

Fig 7. Identification of cellular sources of TGFβ in PBMCs of VL patients (n = 10), ECs (n = 5) and NECs (n = 5).

Fig 7

Total PBMCs were freshly cultured in the presence of PMA (50 ng/μl), ionomycin (1 μg/μl) for 2 hrs and for additional 1 hr in presence of brefeldin A (10μg/μl) before staining. (A) Percentages of CD25+ and CD25− cells among CD4+TGFβ+ cells. (B) Percentages of CD25+ and CD25− cells among CD4+FoxP3+TGFβ+ cells. Data are represented as mean ± SE. P values were calculated using Wilcoxon matched pairs signed rank test for paired samples; P<0.05 was considered significant. (C), (i)-(iv) Data showing one representative healthy control. (D), (i)-(iv) Data showing one representative active VL patient.